Infectious Diseases Pharmacy Specialty Review Course for Recertification, Workbook Chapters + RECERT Assessment Package (Cert # L229162)

The American Society of Health-System Pharmacists and the American College of Clinical Pharmacy are accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

These recertification activities are intended for board certified pharmacists seeking to update their knowledge and skills in infectious diseases pharmacy.

Board certified pharmacists are eligible to receive up to 25 contact hours of recertification credit for completing this course. To earn recertification credit, learners must review the course content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed.  You are allowed only one attempt to successfully complete this assessment.

This course is not intended for those preparing to take the BPS Infectious Diseases Pharmacy Specialty Examination for Certification. To prepare for the examination, please see courses here: http://elearning.ashp.org/catalog/ID-review 

These activities are part of the ASHP and ACCP professional development program for BCIDP recertification approved by the BPS. 

* Please note: Review Course for Recertification may only be completed for recertification credit up to two times, in nonconsecutive years, during the 7-year recertification cycle.

After participating in these CPE activities, learners should be able to: 

Antimicrobial Stewardship
ACPE #: 0204-9999-22-960-H01-P

• Outline components of an effective stewardship program.
• Select appropriate resources; relevant accreditation, legal, regulatory, and safety requirements; and quality metrics related to infectious diseases.
• Evaluate institutional treatment policies and pathways for compliance with antimicrobial stewardship guidelines, surveillance data, and best available evidence.
• Assess the effectiveness of infection prevention strategies.
• Identify metrics for evaluating the value of infectious diseases pharmacy services. 

Upper Respiratory Tract Infections
ACPE #: 0204-9999-22-961-H01-P

• Assess pharmacotherapies for upper respiratory tract infections.
• Select the most appropriate pharmacotherapeutic plan and monitoring based on patient- and disease-specific information, antibiogram data, and best available evidence.
• Recommend modifications of patient-specific treatment plans based on efficacy and adverse effects.
• Identify recommended immunizations and potential adverse effects. 

Lower Respiratory Tract Infections
ACPE #: 0204-9999-22-962-H01-P

• Assess pharmacotherapies for lower respiratory tract infections, including antimicrobial spectrum of activity, pharmacokinetics, and pharmacodynamics.
• Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease-specific information, antibiogram data, and best available evidence.
• Interpret signs, symptoms, and laboratory and other relevant diagnostic test results.
• Recommend the most appropriate modifications of patient‐specific treatment plans based on efficacy, adverse effects, and follow‐up assessment.
• Interpret biomedical literature with regard to study design and methodology, significance of reported data and conclusions, limitations, and applicability of study results to patients with lower respiratory tract infections. 

HIV Infection and AIDS
ACPE #: 0204-9999-22-963-H02-P

• Assess pharmacotherapies for HIV‐infection and AIDS, including opportunistic infections.
• Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease-specific information, antibiogram data, and best available evidence.
• List recommended immunizations and screening guidelines for patients with HIV.
• Recommend modifications of patient‐specific treatment plans based on efficacy, drug interactions, immunologic or virologic response, and adverse effects.
• Interpret signs, symptoms, and laboratory and other relevant diagnostic test results related to HIV infection.
• Evaluate a plan to facilitate transitions of care. 

Infections of Reproductive Organs and Sexually Transmitted Diseases
ACPE #: 0204-9999-22-964-H01-P

• Assess pharmacotherapies for infections of reproductive organs and sexually transmitted diseases.
• Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease-specific information, antibiogram data, and best available evidence.
• Identify recommended screening guidelines for sexually‐transmitted diseases.
• Recommend modifications of patient‐specific treatment plans based on efficacy, immunologic response, and adverse effects.
• Interpret signs, symptoms, and laboratory and other relevant diagnostic test results.
• Summarize key considerations in effective patient and caregiver education and counseling techniques. 

Opportunistic Infections in Immunocompromised Patients
ACPE #: 0204-9999-22-965-H01-P

• Assess the advantages and disadvantages of pharmacotherapies for opportunistic infections in immunocompromised patients, including antimicrobial spectrum of activity, pharmacokinetics, and pharmacodynamics.
• Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease-specific information and best available evidence.
• Interpret signs, symptoms, and laboratory and other relevant diagnostic test results.
• Recommend modifications of patient‐specific treatment plans based on efficacy, immunologic response, and adverse effects.
• Identify preventative therapies in immunocompromised patients. 

Gastrointestinal and Intra-abdominal Infections
ACPE #: 0204-9999-22-966-H01-P

• Assess pharmacotherapies for gastrointestinal and intra‐abdominal infections, including antimicrobial spectrum of activity, pharmacokinetics, and pharmacodynamics.
• Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease-specific information, antibiogram data, and best available evidence.
• Interpret signs, symptoms, and laboratory and other relevant diagnostic test results.
• Recommend modifications of patient‐specific treatment plans based on efficacy, immunologic response, and adverse effects. 

Viral Hepatitis
ACPE #: 0204-9999-22-967-H01-P

• Assess pharmacotherapies for viral hepatitis, including relevant pharmacology and spectrum of activity.
• Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease-specific information, virus and genotype, and best available evidence.
• Interpret signs, symptoms, laboratory and other relevant diagnostic test results.
• Recommend modifications of patient‐specific treatment plans based on efficacy, adverse effects, and drug interactions.
• Summarize key considerations in effective patient and caregiver education and counseling techniques.
• Identify screening guidelines and preventive therapies for viral hepatitis. 

Tuberculosis and Other Mycobacterial Infections
ACPE #: 0204-9999-22-968-H01-P

• Select the most appropriate pharmacotherapeutic plan and monitoring based on patient- and disease-specific information, antibiogram data, and best available evidence.
• Interpret signs, symptoms, laboratory and other relevant diagnostic test results.
• Recommend modifications of patient-specific treatment plans based on efficacy, adverse effects, and drug interactions.
• Outline key considerations in effective patient and caregiver education and counseling techniques.
• Identify screening guidelines and preventive therapies for tuberculosis and other mycobacterial infections. 

Cardiovascular Infections
ACPE #: 0204-9999-22-969-H01-P

• Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease-specific information, antibiogram data, and best available evidence.
• Identify drug‐related problems associated with the therapeutic plan.
• Recommend appropriate modifications of patient‐specific pharmacotherapeutic plans based on efficacy and adverse effects.
• Interpret biomedical literature with regard to study design and methodology, significance of reported data and conclusions, limitations, and applicability of study results to patients with cardiovascular infections. 

Urinary Tract Infections
ACPE #: 0204-9999-22-970-H01-P

• Assess pharmacotherapies for urinary tract infections, including antimicrobial spectrum of activity, pharmacokinetics, and pharmacodynamics.
• Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease-specific information, antibiogram data, and best available evidence.
• Interpret signs, symptoms, laboratory and other relevant diagnostic test results.
• Identify infectious diseases for which notification of the Centers for Disease Control and Prevention is required. 

Statistics, Evidence-based Medicine, and Research Design
ACPE #: 0204-9999-22-905-H04-P

Given an excerpt from a study:

• Evaluate quality and appropriateness of the excerpt, with specific attention to:
  • study design
  • statistical analysis
  • internal/external validity
  • source of bias/confounders
  • quality of conclusions
  • interpretation of graphs.
• Explain why a statistical test is appropriate or not appropriate, based on the sample distribution, data type, and study design.
• Interpret clinical and statistical significance for results from commonly used statistical tests.
• Explain the strengths and limitations of different types of measures of central tendency (mean, median, and mode) and data spread (standard deviation, standard error of the mean, range, and interquartile range).
• Evaluate odds ratio, risk/incidence rate, relative risk, number needed to treat, number needed to harm, and other risk estimates.
• Assess whether the study applies to a specified patient population. 

Bone and Joint Infections and Skin and Soft Tissue Infections
ACPE #: 0204-9999-22-971-H01-P

• Assess the advantages and disadvantages of pharmacotherapies for bone and joint infections and skin and soft tissue infections, including antimicrobial spectrum of activity, pharmacokinetics, and pharmacodynamics.
• Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease-specific information, antibiogram data, and best available evidence.
• Identify drug‐related problems associated with the therapeutic plan.
• Interpret signs, symptoms, and laboratory and other relevant diagnostic test results.
• Recommend appropriate modifications of patient‐specific pharmacotherapeutic plans based on efficacy and adverse effects.
• Describe the etiology, diagnosis, and treatment of acute bacterial osteomyelitis and septic arthritis in pediatric patients. 

Central Nervous System Infections
ACPE #: 0204-9999-22-972-H01-P

• Assess pharmacotherapies for central nervous system infections, including antimicrobial spectrum of activity, pharmacokinetics, and pharmacodynamics.
• Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease-specific information, antibiogram data, and best available evidence.
• Interpret signs, symptoms, and laboratory and other relevant diagnostic test results.
• Identify preventive therapies for central nervous system infections. 

Clinical Microbiology
ACPE #: 0204-9999-22-973-H01-P

• Explain the mechanisms of antimicrobial resistance among various pathogens.
• Identify basic microbiology laboratory procedures.
• Interpret laboratory and other diagnostic test results relevant to the diagnosis, management, and monitoring of patients with infectious diseases.
• Evaluate biomedical literature with regard to study design and methodology specific to infectious diseases.

Full faculty bios

Samuel L. Aitken, PharmD, MPH, BCIDP
Clinical Pharmacy Specialist - Infectious Diseases
University of Michigan Health
Ann Arbor, Michigan 

Eric Egelund, PharmD, PhD, AAHIVE
Clinical Assistant Professor
University of Florida
Jacksonville, Florida 

Kevin W. Garey, PharmD, MS, FASHP, FIDSA*
Professor and Chair
University of Houston College of Pharmacy
Houston, Texas 

Julie Harting, PharmD, BCIDP
Associate Professor / Clinical Pharmacist Specialist, Infectious Disease
Sullivan University College of Pharmacy / University of Louisville Health
Louisville, Kentucky 

Angela Huang, PharmD, BCIDP
Clinical Pharmacy Manager
Honor Health John C. Lincoln Medical Center
Phoenix, Arizona 

David Koren, PharmD, MPH, BCPS, AAHIVP
Clinical Pharmacist Specialist - Infectious Diseases / Adjunct Assistant Clinical Professor
Temple University Health System / Lewis Katz School of Medicine at Temple University
Philadelphia, Pennsylvania 

J. Nicholas O'Donnell, PharmD, MSc, BCPS
Associate Professor
Albany College of Pharmacy and Health Sciences
Albany, New York 

Natasha Pettit, PharmD, BCPS, BCIDP
Pharmacy Director of ASP and Pharmacy Clinical Coordinator, ASP/ID
University of Chicago Medicine
Chicago, Illinois 

Jessica Robinson, PharmD, BCPS, BCIDP
Associate Professor / Associate Director of Antimicrobial Stewardship
University of Charleston School of Pharmacy / Charleston Area Medical Center
Charleston, West Virginia 

Jason J. Schafer, PharmD, MPH, BCPS, BCIDP, AAHIVP*
Professor and Vice Chair, Department of Pharmacy Practice
Jefferson College of Pharmacy
Thomas Jefferson University
Philadelphia, Pennsylvania 

Kayla R. Stover, PharmD, BCPS, BCIDP, FCCP, FIDSA*
Associate Professor of Pharmacy Practice
University of Mississippi School of Pharmacy
Jackson, Mississippi 

Bryan P. White, PharmD, BCPS
Infectious Diseases Clinical Pharmacist
University of Oklahoma Medical Center
Oklahoma City, Oklahoma 

Marylee Worley, PharmD, BCIDP
Assistant Professor
Nova Southeastern University College of Pharmacy
Fort Lauderdale, Florida 

Evan Zasowski, PharmD, MPH, BCIDP, BCPS*
Assistant Professor
Touro University California College of Pharmacy
Vallejo, California 

*Content matter experts

Kristi N. Hofer, PharmD
Susan R. Dombrowski, MS, RPh 

Marwa Ahmed, BPS, BCIDP
Bashayer Alshehail, PharmD, BCIDP
Edward Alvarez, PharmD, BCIDP, BCCCP
Arpita Bhavsar, PharmD, BCIDP
Brian Bohn, PharmD, BCIDP
John Boreyko, PharmD, BCIDP
Andrea Boyce, PharmD, BCIDP
Donna Burgess, RPh, BCIDP
Thanawat Chattaweelarp, PharmD, BCP, BCIDP
Justine Choe, PharmD, BCIDP
Robbie Christian, BS, PharmD, BCIDP, AAHIVP
Jessica Cottreau, PharmD, BCPS, BCIDP
Lydia D'Agostino, PharmD, BCPS, BCIDP
Joanna DeAngelis, PharmD, BCIDP
Alaina DeKerlegand, PharmD, BCIDP
Armisha Desai, PharmD, BCIDP
Alex Dominguez, PharmD, MAS, BCPS, BCIDP
Daniel Echeverria, PharmD, BCIDP, PhD
Jonathan Edwards, PharmD, BCPS, BCGP, BCIDP
Mohammad Elian, BCPS, BCIDP
Yehia Elkhawly, PharmD, BCPS, BCIDP
Dina Elsebaei, PharmD, BCID
Assem Elshafey, BSC, PharmD, BCPS, BCIDP
Jimmy El-Yamani, BCIDP
Fernando Estrada, PharmD, BCPS, BCIDP
Alireza Fakhriravari, PharmD, BCPS, BCIDP, AAHIVP
Jessica Foley, PharmD, BCIDP
Jonathan Ford, PharmD, MBA, BCPS, BCIDP
Mercedes Fraga, PharmD, BCPS, BCCCP, BCIDP
Tiffany Goolsby, PharmD, BCIDP
Tara Harpenau, PharmD, BCIDP
Jason Hedvat, PharmD, BCIDP
Tara Hoop, BCPS, BCIDP
Saeed Hussein, PhD, MSC, BCPS, BCOP, BCCCP, BCIDP 
Melanie Hyte, PharmD, BCIDP
Judith Ikwuagwu, BS, PharmD, BCPS, BCIDP
Duaa Jawhar, BCIDS, MSc
Bronagh Keane, Mpharm, BCPS, BCIDP
Brett Keskes, PharmD, BCIDP
Christine Kubin, PharmD, BCPS, BCIDP
Helen Lee, PharmD, BCPS-AQ ID, BCIDP
Emily Limberg, PharmD, BCIDP
Kayihura Manigaba, PharmD, BCIDP
Kassandra Marsh, PharmD, BCIDP
Kelley Merrick, PharmD, PhC, BCIDP
Jessica Miller, PharmD, BCIDP
Justin Moore, PharmD, BCPS, BCIDP
Grace Mortrude, PharmD, BCIDP
Rachel Musgrove, PharmD, BCIDP
Ching Zin Ngua, PharmD, BCIDP
Yosef Nissim, PharmD, BCIDP
Eun Park, PharmD, BCPS, BCIDP
Pratish Patel, PharmD, BCIDP, AAHIVP
Saloni Patel, PharmD, BCIDP
Shiv Patel, PharmD, BCPS, BCIDP
Sonal Patel, PharmD, BCIDP
Ursula Patel, PharmD, BCPS, BCIDP
Kamryn Plechot, PharmD, BCIDP
Anna Poston-Blahnik, PharmD, BCIDP
Kimberly Pough, PharmD, BCPS, BCIDP
Yinghui Pu, PharmD, BCPS, BCIDP
Lauren Puckett, PharmD, BCIDP
Aundrea Rosenberger, PharmD, BCIDP
Alanna Rufe, PharmD, BCIDP
Justin Schmetterer, PharmD, PhC, BCIDP
Emily Sinclair, PharmD, BCPS, BCIDP
Karla Killgore Smith, PharmD, BCPS, BCIDP
Jessica Sobnosky, PharmD, BCPS, BCIDP
Obioma Ubaka, PharmD, BCPS, BCIDP
Mary Ullman, PharmD, BCPS, BCIDP
Mollie VanNatta, PharmD, BCPS, BCIDP
Jill Waldhoff, PharmD, BCPS, BCIDP, CACP
Limei Wang, PharmD, BCIDP
Eric Wombwell, PharmD, BCIDP
Kar Loon Wong, BCIDP
Victoria Woolley, PharmD, BCIDP
Arsheena Yassin, PharmD, BCIDP
Lisa Young, PharmD
Min Zhang, PharmD, BCPS, BCIDP
Yvonne Zhou, MSc, BCIDP

In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.

The following persons in control of this activity’s content have relevant financial relationships:

• Kevin Garey: Research grant, Paratek Pharmaceuticals
• David Koren: Advisor, Gilead; Independent Contractor, Abbvie
• Jason Schafer: Advisor/research grant, Merck; Research grant, Gilead
• Kayla Stover: Advisory Board, Cidara TherapeuticsKevin Garey: Research grant, Acurx; Research grant, Summit; Research grant, Tetraphase; Research grant, Paratek Pharmaceuticals 

All other persons in control of content do not have any relevant financial relationships with an ineligible company. 

As required by the Standards of Integrity and Independence in Accredited Continuing Education, all relevant financial relationships have been mitigated prior to the CPE activity.

Activities can be completed in any order. Each activity consists of audio, video, and/or PDFs and evaluations. Learners must review all content and complete the evaluations to receive continuing pharmacy education credit for each activity. 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

These activities were developed by ASHP and ACCP.